Demystifying Medicine Video



This video explains HIV pre-exposure prophylaxis, also known as HIV PrEP, as a means to prevent HIV-1 infection. It covers a short description of what HIV is and some key players that assist in infecting the body. It focuses on Truvada, the only approved HIV PrEP treatment in Canada and the United States.


[Please complete our feedback form]



References
  • HIV, C. (2012). Aids. Medical Care, 916, 874-7720.
  • Palios, J., Kadoglou, N. P., & Lampropoulos, S. (2011). The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders. Journal of Diabetes Research, Experimental Diabetes Research, Volume 2012 (2012), Article ID 103063.
  • De Clercq, E. (2012). The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). Advances in pharmacology (San Diego, Calif.), 67, 317-358) .
  • Ware, N. C., Wyatt, M. A., Haberer, J. E., Baeten, J. M., Kintu, A., Psaros, C., ... & Bangsberg, D. R. (2012). What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV serodiscordant couples. Journal of acquired immune deficiency syndromes (1999), 59(5)
  • PrEP | HIV Basics | HIV/AIDS | CDC. (2017). Cdc.gov. Retrieved 27 January 2017.
  • Pizzuti, M. (2017). Who should or shouldn’t be on PrEP? A physician explains. Pivot. Retrieved 27 January 2017.
  • Gilead Sciences. (2016). Truvada: Highlights of Prescribing Information. Retrieved 27 January 2017.
  • Peterson, L., Taylor, D., Roddy, R., Belai, G., Phillips, P., Nanda, K., ... & Jaffe, H. S. (2007). Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLOS Clin Trial, 2(5), e27.
  • Sharma, M., & Tan, D. H. (2014). HIV pre-exposure prophylaxis. Canadian Medical Association Journal, 186(15), E588-E588.
  • Grant, R. M., Anderson, P. L., McMahan, V., Liu, A., Amico, K. R., Mehrotra, M., ... & Buchbinder, S. (2014). Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. The Lancet infectious diseases, 14(9), 820-829.
  • Spinner, C. D., Boesecke, C., Zink, A., Jessen, H., Stellbrink, H. J., Rockstroh, J. K., & Esser, S. (2016). HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection, 44(2), 151-158.
  • Hosek, S., Siberry, G., Bell, M., Lally, M., Kapogiannis, B., Green, K., ... & Wilson, C. (2013). Project PrEPare (ATN082): The acceptability and feasibility of an HIV pre-exposure prophylaxis (PrEP) trial with young men who have sex with men (YMSM). Journal of acquired immune deficiency syndromes (1999), 62(4).